sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
Search
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Positive-CHMP-opinion-for-dabigatran-in-children
Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Meet the BD&L Team 2019
Hear from our team and find out more about our approach to partnering.
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Sustainable medicines that help minimize environmental impact
How we collaborate with renowned experts to lead the way in reducing solvent waste, as part of our efforts to embed sustainability into our core business.
How Boehringer Ingelheim is Supporting Grass Roots Innovation
Our Grass Roots activities support life-science innovators with mentoring and networking opportunities.
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim
Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
Implementing the generalized pustular psoriasis (GPP) Charter
Read more about the projects are implementing the generalized pustular psoriasis (GPP) Charter
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Connect with Us
Human Health Partnering Connect with Us
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Kicking off 2024 with five new R&D partnerships
We are kicking off 2024 with five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide.
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
LastMile initiative to address barriers in animal healthcare
The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
2024 half year results innovation progress
First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones
Generalized pustular psoriasis is not ‘sensitive’ content
Learn about the impact that a lack of online visibility can have on people living with this chronic, inflammatory skin disease.